Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for BPSD in Alzheimer's Disease
NCT00626613Phase 4Unknown
- Sponsor
- Jinan Mental Health Center
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Dementia comparing Risperidone with Placebo (2 arms). Primary endpoints: Neuropsychiatric Inventory at 12 weeks, Cognitive Abilities Screening Instrument at 12 weeks and 5 more. Status: unknown.
02
Drugs
risperidone
03
Conditions
Dementia
Beyond the preview
Go deeper on NCT00626613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626613.